Laboratory tests for live attenuated poliovirus vaccines

Biologicals

Volumn 25, Issue 1, 1997, Pages 3-15

  Wood, D J ^a   Macadam, A J ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; POLIOMYELITIS VACCINE; RESTRICTION ENDONUCLEASE; VIRUS RECEPTOR;

ATTENUATION; CONTROL; DRUG POTENCY; LABORATORY TEST; MOLECULAR BIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERTANT; REVIEW; STANDARDIZATION; THERMOSTABILITY; TRANSGENIC MOUSE; VIRUS VIRULENCE; WORLD HEALTH ORGANIZATION;

MUS MUSCULUS; POLIOVIRUS;

EID: 0031105157     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1997.0055     Document Type: Article

References (75)

1. 1. Minor PD. Polioviruses. In Encyclopedia of Virology ISBN 0-12-226960-8, London: Academic Press Ltd, 1994.
2. 2. Mendelsohn CL, Wimmer E and Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence and expression of a new member of the immunoglobulins superfamily. Cell 1989; 56: 855-865.
3. 3. Koike S, Horie H, Ise I et al. The poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO J 1990; 9: 3217-3224.
4. 4. Koike S, Ise I, Sato Y et al. A second gene for the African green monkey poliovirus receptor that has no putative N-glycosylation site in the functional N-terminal immunoglobulin-like domain. J Virol 1992; 66: 7059-7066.
5. 5. World Health Organization. Requirements for poliomyelitis vaccine (oral), Technical Report Series 1990; 800: 30-86.
6. 6. Sabin AB and Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1973; 1: 115-118.
7. 2 attenuated poliovirus. Acta Microbiologia Sinica 1976; 16: 41-47 (In Chinese).
8. 8. Stones PB, MacDonld CR, McDougall JK et al. Preparation and properties of a derivative of Sabin's type 3 poliovirus strain Leon 12a, b. 10th Symposium of the European Association against poliomyelitis, Warsaw, 1964, pp 390-397.
9. 9. Montagnon BJ. Polio and rabies vaccines produced in continuous cell lines: reality for Vero cell line. Dev Biol Stand 1989; 70: 27-48.
10. 10. Melnick JL, Ashkenazi A, Midulla UC et al. J Am Med Assoc 1963; 185, 406-408.
11. 11. Minor PD. Use of animals in the development and control of viral vaccines. Dev Biol Stand 1996; 86: 113-120.
12. 12. Boulger LR, Marsden SA, Magrath DI et al. Comparative monkey neuro virulence of Sabin type III poliovirus vaccines. J Biol Stand 1979; 7: 97-111.
13. 13. Boulger LR, Magrath DI. Differing neurovirulence of three Sabin attenuated type 3 vaccine seed pools and their progeny. J Biol Stand 1973; 1: 139-147.
14. 14. Furesz J, Contreras G. Some aspects of the monkey neurovirulence test used for the assessment of oral poliovirus vaccines. Dev Biol Stand 1993; 78: 61-70.
15. 15. Magrath DI, Reeve P. On the role of the World Health Organization in the development of Sabin vaccines. Biologicals 1993; 21: 345-348.
16. 16. Contreras G, Furesz J, Karpinski K et al. Experience in Canada with the new revised monkey neurovirulence test for oral poliovirus vaccine. J Biol Stand 1988; 16: 195-205.
17. 17. Wood DJ, Heath AB, Marsden SA. A collaborative study of the histopathological evaluation of the WHO neurovirulence test for poliovirus vaccines. Biologicals 1994; 22: 45-51.
18. 18. Contreras G, Furesz J. Possible influence of measles virus infection of cynomolgus monkeys on the outcome of the neurovirulence test for oral poliovirus vaccine. Biologicals 1992; 20: 27-33.
19. 19. Sabin AB. Reflections on the qualitative and quantitative aspects of neurovirulence of different polioviruses. Dev Biol Stand 1993; 78: 3-7.
20. 20. WHO Consultative Group. The relation between acute persisting spinal paralysis and poliomyelitis vaccine - results of a ten-year enquiry. Bull WHO 1982; 60: 231-242.
21. 21. Joce R, Wood DJ, Brown D, Begg N. Paralytic poliomyelitis in England and Wales, 1985-91. Br Med J 1992; 305: 79-82.
22. 22. Wood DJ. Evaluation of new approaches to poliovirus vaccine neurovirulence tests. Dev Biol Stand 1996; 86: 79-84.
23. 23. Toyoda H, Kohara M, Kataoka Y et al. Complete nucleotide sequence of all three poliovirus serotypes. J Mol Biol 1984; 174: 561-585.
24. 24. Westrop GD, Evans DMA, Dunn G et al. Genetic basis of attenuation of the Sabin Type 3 oral poliovaccine. J Virol 1989; 63: 1338-1344.
25. 25. Pollard SR, Dunn G, Cammack N et al. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J Virol 1989; 63: 4949-4951.
26. 26. Omata T, Kohara M, Kuge S et al. Genetic analysis of the attenuation phenotype of poliovirus type 1. J Virol 1986; 58: 348-358.
27. 27. Racaniello VR, and Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 1981; 214: 916-919.
28. 28. Van der Werf S, Bradley J, Wimmer E et al. Synthesis of infectious poliovirus RNA by purified T7 polymerase. Proc Natl Acad Sci USA 83: 2330-2334.
29. 29. Tatem JM, Weeks-Levy C, Georgiu A et al. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. J Virol 1992; 66: 3194-3197.
30. 30. Macadam AJ, Pollard SR, Ferguson G et al. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 1993; 192: 18-26.
31. 31. Ren R, Moss EG, Racaniello VR. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol 1991; 65: 1377-1382.
32. 32. Kawamura N, Kohara M, Abe S et al. Determinants in the 5′ non-coding region of poliovirus Sabin 1 RNA that influence that attenuation phenotype. J Virol 1989; 63: 1302-1309.
33. 33. Horie H et al. Transgenic Mice Carrying the Human Poliovirus Receptor: New Animal Model for Study of Poliovirus Neurovirulence. J Virol 1994; 68: 681-688.
34. 34. Tardy-Panit M et al. A Mutation in the RNA Polymerase of Poliovirus type 1 Contributes to Attenuation in Mice. J Virol 1993; 67: 4630-4638.
35. 35. Christodoulou C, Colbere-Garapin F, Macadam AJ et al. Mapping of mutations associated with monkey neurovirulence of Sabin 1 poliovirus revertants selected at high temperature. J Virol 1990; 64: 4922-4929.
36. 36. McGoldrick A, Macadam AJ, Dunn G et al. Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol 1995; 69: 7601-7605.
37. 37. Bouchard MJ, Lam D-H, Racaniello VR. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol 1995; 69: 4972-4978.
38. 38. Beynish-Melnick M, Melnick JL. The use of in vitro markers and monkey neurovirulence tests to follow genetic changes in attenuated poliovirus multiplying in the human alimentary tract. In 'First International Conference on Live poliovirus Vaccines' Pan American Sanitary Bureau, Washington, USA, 1959; 179-198.
39. 39. Melnick JL, Beynish-Melnick M. Problems associated with live poliovirus vaccine and its progeny after multiplication in man. In 'Second International Conference on Live Poliovirus Vaccines' Pan American Health Organisation Scientific Publication No 50, Washington, USA 1960. pp 12-27.
40. 40. Contreras G, Dimmock K, Furesz J et al. Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals, 1992; 20: 15-26.
41. 41. Nkowane BM, Wassilak SG, Orenstein WA. Vaccine associated paralytic poliomyelitis, United States: 1973 through 1984. J Am Med Assoc 1987; 257: 1335-1340.
42. 42. Macadam AJ, Arnold C, Hewlett J et al. Reversion of attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 1989; 174: 408-414.
43. 43. Georgescu M-M, Delpeyroux F, Tardy-Panit M et al. High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol 1994; 68: 8089-8101.
44. 44. Abe S, Ota Y, Doi Y et al. Studies on neurovirulence in poliovirus-sensitive transgenic mice and cynomolgus monkeys for the different temperature sensitive viruses derived from the Sabin type 3 virus. Virology 1995; 210: 160-166.
45. 45. Minor PD, Dunn G, Evans DMA et al. The temperature-sensitivity of the Sabin type 3 vaccine strain of poliovirus: Molecular and structural effects of a mutation in the capsid protein VP3. J Gen Virol 1989; 70: 1117-1123.
46. 46. Filman DJ, Syed R, Chow M et al. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J 1989; 8: 1567-1579.
47. 47. Macadam AJ, Ferguson G, Arnold C and Minor PD. An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain. J Virol 1991; 65: 525-531.
48. 48. Skinner MA, Racaniello VR, Dunn G et al. New model for the secondary structure of the 5′ non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that secondary structure is important in neurovirulence. J Mol Biol 1989; 207: 379-392.
49. 49. Macadam AJ, Ferguson G, Burlison J et al. Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue-culture. Virology 1992; 189: 415-422.
50. 50. Svitkin YV, Cammack N, Minor PD et al. Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472-U. Virology 1990; 175: 103-109.
51. 51. Ward C, Flanegan JB. Determination of the poliovirus RNA polymerase error frequency at eight sites in the viral genome. J Virol 1992; 66: 3784-3793.
52. 52. Rezapkin GV, Norwood LP, Taffs RE et al. Microevolution of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control. Virology 1995; 211: 377-384.
53. 53. Rezapkin GV, Chumakov KM, Lu Z et al. Microevaluation of Sabin 1 strain in vivo and genetic stability of oral poliovirus vaccine. Virology 1994; 202: 370-378.
54. 54. Taffs RE, Chumakov M, Rezapkin GV et al. Genetic stability and mutant selection of Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions. Virology 1995; 209: 366-373.
55. 55. Chumakov KM, Dragunsky EM, Norwood LP et al. Consistent selection of mutations in the 5′ untranslated region of oral poliovirus vaccine upon passaging in vitro. J Med Virol 1994; 42: 79-85.
56. 56. Chumakov KM, Powers LB, Noonan KE et al. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Nat Acad Sci USA 1991; 88: 199-203.
57. 57. Chumakov KM, Norwood LP, Parker ML et al. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J Virol 1992; 66: 966-970.
58. 58. Wood DJ. New approaches to poliovirus vaccine neurovirulence tests: transgenic mice susceptible to poliovirus and molecular analysis of poliovirus. A meeting report of the WHO Global Programme for Vaccines and Immunization and the WHO Biologicals Unit. Vaccine, (in press).
59. 59. Ren R, Costantini F, Gorgacz EJ et al. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 1990; 63: 353-362.
60. 60. Koike S, Taya C, Kurate T et al. Transgenic mice susceptible to poliovirus. Proc Nat Acad Sci USA 1991; 88: 951-955.
61. 61. Wood DJ, Marsden SA, Nomoto A. Transgenic mice: a new model for poliovirus vaccine testing. Scand J Lab Animal Sci, 1996; 23 (Suppl 1): 263-267.
62. 62. Koike S, Taya C, Aoki J et al. Characterization of three different transgenic mouse lines that carry human poliovirus receptor gene - influence of the transgene expression of pathogenesis. Arch Virol 1994; 139: 351-363.
63. 63. Nomura T and Hioki K. Systems for development of transgenic animals as laboratory animals. Scand J Lab Animal Sci, in press.
64. 64. Abe S, Ota Y, Koike S et al. Neurovirulence test for oral live poliovaccines using polio-sensitive transgenic mice. Virology 1995; 206: 1075-1083.
65. 65. World Health Organization. Requirements for poliovirus vaccine (oral). Technical Report Series 1962; 237: 23.
66. 66. Sabin AB, Lwoff A. Relation between reproductive capacity of polioviruses at different temperatures in tissue culture and neurovirulence. Science 1959; 129: 1287-1288.
67. 67. Vogt M, Dulbecco R, Wenner HA. Mutants of poliomyelitis viruses with reduced efficiency of plating in acid medium and reduced neuropathologenicity. Virology 1957; 4: 141-155.
68. 68. Hsuing GD, Melnick JL. Effect of sodium bicarbonate concentration on plaque formation of virulent and attenuated polioviruses. J Immunol 1958; 80: 282-293.
69. 69. Anonymous. Markers of poliovirus strains isolated from cases temporally associated with the use of live poliovirus vaccine: report on a WHO Collaborative study. J Biol Stand 1981; 9: 163-184.
70. 70. Macadam AJ, Pollard SR, Ferguson G et al. The 5′ non-coding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature-sensitivity. Virology 1991; 181: 451-458.
71. 71. Georgescu M-M, Tardy-Panit M, Guillot S et al. Mapping of mutations contributing to the temperature sensitivity of the Sabin vaccine strain of poliovirus. J Virol 1995; 69: 5278-5286.
72. 72. Macadam AJ Ferguson G, Fleming T et al. Role for poliovirus protease 2A in cap-independent translation. EMBO J 1994; 13: 924-927.
73. 73. Pipkin PA, Wood DJ, Racaniello VR et al. Characterization of L cells expressing the human poliovirus receptor for the specific detection of polioviurses in vitro. J Virol Methods 1993; 41: 333-340.
74. 74. Magrath DI and Seagroat V. The standardization of infectivity titrations of poliovaccines - a WHO Collaborative study. J Biol Stand 1985; 13: 159-166.
75. 75. World Health Organization. Manual of laboratory methods for testing the potency of final vaccines used in the WHO Expanded Programme on Immunization. 1995; WHO/BLG/95.1.